Life Sciences

life-sciences-icon
A Blueprint for Biosimilars?
As expected, biosimilars news made top headlines right out of the starting gate in 2015, with Novartis’s biosimilars version of filgrastim gaining a 14-0 positive vote by the FDA’s independent Oncologic Drugs Advisory Committee on